By Colin Kellaher


Voyager Therapeutics Inc. on Tuesday said Pfizer Inc. exercised one of two options to license a novel capsid generated from its Tracer capsid discovery platform, letting the second option lapse.

The Cambridge, Mass., gene-therapy company said Pfizer's exercise of the option targeting an undisclosed rare neurologic disease triggers a $10 million payment from the New York drugmaker.

Last October, Voyager said it had inked an agreement with Pfizer for the two options, targeting central-nervous-system and cardiovascular diseases. Voyager received $30 million upfront and was eligible for up to $20 million in exercise fees, as well as up to $580 million in potential milestone payment.

Voyager said it remains eligible for up to $290 million in milestone payments related to the neurologic disease, while all rights to the capsid for a cardiovascular disease target revert to the company.


Write to Colin Kellaher at


(END) Dow Jones Newswires

October 04, 2022 07:44 ET (11:44 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 11 2022 まで 12 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 12 2021 まで 12 2022 Pfizerのチャートをもっと見るにはこちらをクリック